针对固体瘤的有效CAR-T细胞免疫疗法的挑战和策略
Guangxun Yuan1, Mengke Ye1, Yixi Zhang2
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
化学抗原受体T细胞 (CAR-T) 疗法对固体瘤具有前景. 审查了克服瘤微环境中CAR-T细胞局限性的策略,以改善癌症治疗.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法已经改变了癌症治疗.
- 显著的挑战阻碍了CAR-T在固体瘤中的应用,包括透和瘤微环境中的生存.
研究的目的:
- 审查加强CAR-T细胞透,疗效,抗原识别和固体瘤中的产生策略.
- 探索其他CAR-T细胞应用,包括CAR-γδ T细胞和巨细胞.
主要方法:
- 关于固体瘤CAR-T疗法的当前研究的文献综述.
- 对瘤微环境中的CAR-T细胞功能的挑战和建议解决方案的分析.
主要成果:
- 确定了固体瘤中CAR-T细胞的关键局限性:透,存活,增殖和功能不佳.
- 总结了提高CAR-T细胞性能的策略,包括改善抗原识别和产生.
- 讨论了CAR-γδ T细胞和巨细胞作为替代治疗剂的潜力.
结论:
- 克服瘤微环境中的挑战对于CAR-T疗法成为固体瘤治疗的里程碑至关重要.
- 对加强CAR-T细胞能力的进一步研究将释放它们对抗固体瘤的全部潜力.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
